All In Biotech

Drug Trial Radar · NCT07227025

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Nov 30, 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AmivantamabDrug

    Amivantamab will be administered.

  • OlomorasibDrug

    Olomorasib will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to approximately 3 years 2 months
  2. Phase 1: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 3 years 2 months
  3. Phase 2: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 3 years 2 months

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • New York University Langone Medical Center

    New York, New York · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Princess Margaret Hospital

    Toronto, Ontario, Canada · Recruiting

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, China · Recruiting

  • Harbin medical university cancer hospital

    Harbin, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Bilkent Sehir Hastanesi

    Çankaya, Turkey (Türkiye) · Recruiting

  • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.